lundi 20 avril 2015

Onco Actu - Spécial AACR 2015

A lire aussi : l'autre billet du jour

5.9 AACR

New Immunotherapy Advances Presented at the AACR Annual Meeting 2015 [CANCER RESEARCH Catalyst]

5.9.2 AACR - hémato

New T Cell–based Immunotherapy Shows Promise for Lethal Stem Cell Transplant Complication [AACR]

5.9.3 AACR - mélanome

Combining Two Investigational Immunotherapy Drugs Safe, With Early Signs of Effectiveness [AACR]

KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy in a Phase 3 Study of Patients with Advanced Melanoma [Merck]

New Immunotherapy Yields Long-lasting Responses in Some Patients With Advanced Melanoma [AACR]

Pembrolizumab is Better Than Ipilimumab for Advanced Melanoma in Phase III Trial [AACR]

Immunocore Announces Positive Clinical Trial Data for Novel First-in-Class Immunotherapy at AACR Annual Meeting 2015 [Immunocore]

Merck Cancer Drug Shines Against Skin, Lung Cancer [Forbes]

Merck Drug Shows Improved Odds for Melanoma Patients [Wall Street Journal]

5.9.4 AACR - poumon

Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA® (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine [Merck]

Pembrolizumab Promising for Lung Cancer, Clinical Outcomes Correlate With Biomarker [AACR]

Merck's Keytruda shrinks lung cancer tumors, FDA approval sought [Reuters]

5.9.5 AACR - CAR-T

Investigational CART-meso Immunotherapy Feasible for Patients With Advanced Cancers [AACR]

Immune Cell Cancer Immunotherapy Passes First Safety Test in Solid Tumors [TheStreet]

5.9.6 AACR - divers

Adding a Dual mTOR Inhibitor to Chemotherapy May Benefit Some Ovarian and Lung Cancer Patients [AACR]

Combining Chk1 Inhibition With Standard Dose Gemcitabine May be Safe and Effective [AACR]

Early Findings with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting [Merck]

“Liquid Biopsy” May Help Earlier Detection of Lung Cancer Treatment Resistance [AACR]

Long-term, Regular Aspirin Use Modestly Decreased Cancer Risk [AACR]

Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel CancerDrug Targets [Blueprint Medicines]

Pembrolizumab Safe, With Signs of Clinical Benefit, for Patients With Malignant Pleural Mesothelioma [AACR]